Combined treatment with a BRAF inhibitor and a MEK inhibitor resulted in modest clinical efficacy in a group of patients whose melanoma had progressed after prior treatment with a BRAF inhibitor, results of a new study published in the Journal of Clinical Oncology show.
MRV Research
New melanoma drug therapy improves survival rate while lowering chances of side effects
Comprehensive Cancer Center has helped develop a combination drug therapy that shows promise in extending the lives of people with metastatic melanoma. This new therapy also accomplishes this without the side effect of a secondary skin cancer seen in some patients prescribed only one of the drugs.
BMS Launches Cancer-Combo Collaborations with Novartis, MD Anderson
Bristol-Myers Squibb (BMS) today disclosed a pair of combination-therapy cancer collaborations involving its Opdivo (nivolumab)—a clinical trial partnership to assess the effect of the investigational immunotherapeutic with Novartis’ Zykadia (ceritinib) and two drug candidates; and a clinical research partnership with the University of Texas MD Anderson Cancer Center to evaluate Opdivo, the already-marketed Yervoy (ipililumab) and three BMS drug candidates.
BRAF/MEK Combo Active in BRAF-Resistant Melanoma
Combined treatment with a BRAF inhibitor and a MEK inhibitor resulted in modest clinical efficacy in a group of patients whose melanoma had progressed after prior treatment with a BRAF inhibitor, results of a new study published in the Journal of Clinical Oncology show.